In a placebo-controlled phase II trial (NeoPHOEBE), addition of the pan-PI3K inhibitor buparlisib to taxane-trastuzumab-based therapy in HER2 positive early breast cancer was revealed to be unfeasible [121]. This evidence concerns the gene PIK3CA and breast cancer.